Stay informed with the latest litigation news. Explore now

IP Verse

Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes - EP3152234B2

EP3152234

CELLVAX
Application Number
EP15732846A
Filing Date
Jun 5, 2015
Status
Patent Maintained As Amended
May 24, 2024
Grant Date
Jun 26, 2024
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3152234B2 was granted to Cellvax on Jun 26, 2024 following the initial filing on Jun 5, 2015 under the application number EP15732846A . The current legal status of the patent is Patent Maintained As Amended.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEApr 8, 2021WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents